Image: Silvio Rahr (Managing Director of Wir für Gesundheit GmbH) and Prof. Dr. Hartmut Göbel (Chief Physician of the Kiel Pain Clinic). The Kiel Pain Clinic is a new partner of the growing, cross-institutional quality network "Wir für Gesundheit" (We for Health). The network comprises more than 230 [...]
For over ten years, we have been conducting the "Stop the Headache" program, developed by Heide Denecke and Birgit Kröner-Herwig, in an outpatient setting in close cooperation with Techniker Krankenkasse (a German health insurance company). Building on this, we developed a [...]
On May 2, 2019, the Federal Joint Committee (G-BA) adopted the benefit assessment of erenumab in accordance with Section 35a of the German Social Code, Book V (SGB V). A considerable additional benefit was derived from the submitted data only for adult patients, which did not [...]
The third edition of the International Classification of Headache Disorders (ICHD-3) is now available digitally in German. The digital ICHD-3 makes it much easier to understand the structure and content of the current classification. The practical [...]
What role do triggers play in migraines? The word trigger means something that starts a process. It's like a rifle. When you pull the trigger, the shot goes off. A small event sets off a complex sequence of events. The [...]
According to current understanding, migraine pain is based on a neurogenic inflammatory reaction in the arteries of the meninges. Inflammatory substances are released there in the initial stage of a migraine attack. These lead to increased pain sensitivity of the meninges with swelling and dilation [...]
Foreword to the book by Dr. Martin Leonhard: "Success Factors of My Kiel Migraine Kit" Headaches are the number one public health problem; tension headaches and migraines are the most common neurological disorders in humans. Within a year, [...]
Following erenumab (Aimovig®) on November 1, 2018, the second antibody, galcanezumab (Emgality®), for migraine prophylaxis will also be available in Germany on April 1, 2019. Galcanezumab has been approved in the EU since November 2018. The [...]
Successful as a prophylaxis when other drug therapies have been exhausted: Erenumab, the first drug in a new class for migraine prophylaxis, was launched on the German market in November 2018. An early benefit assessment has shown that [...]
London, 10 January 2019. The National Institute for Health and Care Excellence (NICE) is evaluating guidelines for health technologies, clinical care practices, and prevention on behalf of the UK Department of Health. The [...]
How common is migraine in children? 73.9 percent of seventh graders complain of primary headaches. The most common forms are migraine and tension-type headaches. Nearly 50% of those affected report migraine symptoms [...]
Migraine is the third most common human disease worldwide, after dental caries and tension-type headache [28]. The one-year prevalence in Europe for all forms of migraine is 43.6% in women and 26.9% in men [...]
Headaches are a major problem for Germany's young academics. Around 1.8 million of the 2.8 million students in Germany suffer from them. Almost one in three of them is severely affected by headaches. This is the highest level of severity [...]
The Kiel Pain Clinic is a new partner of the growing, cross-institutional quality network "Wir für Gesundheit" (We for Health). The network comprises more than 220 selected partner clinics and numerous outpatient facilities throughout Germany, all offering above-average treatment and service quality [...]
The third edition of the International Classification of Headache Disorders (ICHD-3) is now available in its final form in German translation. It can be viewed on the ICHD-3 website via the link https://www.ichd-3.org/ichd-3-translations/. In particular [...]
Headaches and migraines not only impair the lives of those affected, but also cause economic damage. Newly developed antibodies specifically target the molecular development process of migraines and can thus preventively reduce the likelihood [...]
The first week of September is used internationally to raise awareness about migraines and highlight the significant impact of this health problem. The aim is to reduce prejudice and stigma. Professor Hartmut Göbel answers current questions about migraines and their effects [...]
Kiel, August 1, 2018. The Minister-President of Schleswig-Holstein, Daniel Günther, today presented the Order of Merit of the Federal Republic of Germany, First Class, awarded by Federal President Frank-Walter Steinmeier, to [name omitted] in the presence of Health Minister Dr. Heiner Garg, District President Dr. Juliane Rumpf, and numerous other distinguished guests. [...]
July 30, 2018. Migraine immunotherapy with the active ingredient erenumab (Aimovig) can now also be marketed in the EU. It was initially approved in the US in May 2018, followed by approval in Switzerland in July. Now, the [...]
In the FAZ study "Germany's Best Hospitals," the Kiel Pain Clinic holds the top position nationwide among specialized inpatient pain therapy clinics. Based on all approximately 2,000 hospitals in Germany, it was ranked among the top 10 clinics [...]
